Literature DB >> 7689082

Myocardial injury: the acute phase response and lipoprotein metabolism.

R S Rosenson1.   

Abstract

Myocardial infarction and other types of tissue injury generate changes in plasma proteins known as the acute phase response. Variations in lipid and lipoprotein levels after acute myocardial infarction are manifest within 24 to 48 h after the onset of chest pain. Maximal postinfarction reductions in total cholesterol occur at days 4 to 5 with levels 47% below baseline; low and high density lipoprotein cholesterol fractions decrease to their nadir on day 7 to concentrations that are 48% and 32% below baseline, respectively. Triglyceride levels increase after acute myocardial infarction to a maximal level that is 58% above baseline on day 7. These alterations in lipid and lipoprotein levels generally stabilize by 2 months after the acute event. Screening for dyslipidemias in survivors of myocardial infarction requires clinical decision-making based on accurate and reliable measurements. The clinician must be familiar with characteristic changes in acute phase lipids and lipoproteins to ensure that patients receive appropriate, potentially life-saving therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689082     DOI: 10.1016/0735-1097(93)90213-k

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  40 in total

Review 1.  In-hospital initiation of statin therapy in patients with acute coronary events.

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

2.  Prevalence of Achilles tendon xanthoma and familial hypercholesterolemia in patients with coronary artery disease undergoing percutaneous coronary intervention.

Authors:  Hideki Kitahara; Naoto Mori; Yuichi Saito; Takashi Nakayama; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2019-04-09       Impact factor: 2.037

3.  Adrenal-exhaustion syndrome in patients with liver disease.

Authors:  Paul E Marik
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

Review 4.  Management of dyslipidemia: an update.

Authors:  Cynthia A Sanoski
Journal:  Curr Atheroscler Rep       Date:  2003-07       Impact factor: 5.113

Review 5.  LOX-1, a new marker of risk and prognosis in coronary artery disease?

Authors:  Valter Lubrano; Silvana Balzan
Journal:  Mol Cell Biochem       Date:  2013-08-11       Impact factor: 3.396

Review 6.  Consensus statement on management of dyslipidemia in Indian subjects.

Authors:  K Sarat Chandra; Manish Bansal; Tiny Nair; S S Iyengar; Rajeev Gupta; Subhash C Manchanda; P P Mohanan; V Dayasagar Rao; C N Manjunath; J P S Sawhney; Nakul Sinha; A K Pancholia; Sundeep Mishra; Ravi R Kasliwal; Saumitra Kumar; Unni Krishnan; Sanjay Kalra; Anoop Misra; Usha Shrivastava; Seema Gulati
Journal:  Indian Heart J       Date:  2014-12-24

7.  Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Xiaoqing Fu; Katherine Liao; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; Yuqing Zhang; Hyon Choi; John H Stone
Journal:  Arthritis Rheumatol       Date:  2019-09-16       Impact factor: 10.995

Review 8.  Statin therapy after acute myocardial infarction: are we adequately treating high-risk patients?

Authors:  Gregg C Fonarow
Journal:  Curr Atheroscler Rep       Date:  2002-03       Impact factor: 5.113

9.  Myocardial infarction does not affect fatty-acid profiles in rats.

Authors:  Gregory C Shearer; Jinghai Chen; Yuefeng Chen; William S Harris
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2009-09-22       Impact factor: 4.006

10.  Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.

Authors:  Dagmar Vondrakova; Petr Ostadal; Andreas Kruger
Journal:  Lipids Health Dis       Date:  2010-07-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.